Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.
| Revenue (Most Recent Fiscal Year) | $3.94M |
| Net Income (Most Recent Fiscal Year) | $-131.21M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 16.69 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.52 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2326.34% |
| Net Margin (Trailing 12 Months) | -2337.24% |
| Return on Equity (Trailing 12 Months) | -22.41% |
| Return on Assets (Trailing 12 Months) | -12.09% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.31 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.31 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-7.50 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.53 |
| Earnings per Share (Most Recent Fiscal Year) | $-13.58 |
| Diluted Earnings per Share (Trailing 12 Months) | $-19.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 6.15M |
| Free Float | 5.86M |
| Market Capitalization | $52.96M |
| Average Volume (Last 20 Days) | 0.10M |
| Beta (Past 60 Months) | 2.77 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 60.43% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |